From Nasdaq: 2025-04-26 00:06:00

Innovent Biologics Inc. receives NMPA approval for limertinib as a first-line treatment for NSCLC patients with specific mutations. The drug is set to enter the market in Mainland China in 2024 through a collaboration with ASK Pharm. The approval was based on positive results from a Phase 3 clinical trial with 337 patients, showing improved progression-free survival compared to gefitinib. For more health news, visit rttnews.com.



Read more at Nasdaq: Innovent Biologics : China’s NMPA Approves Limertinib For The First-line Treatment Of Lung Cancer